

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Gloperba (colchicine oral solution)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Gloperba (colchicine oral solution)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Gloperba (colchicine oral solution) may be approved when the following criteria are met:

- I. Individual is using for the prophylaxis of gout flares and one of the following:
 - A. Individual will be initiating or has initiated urate-lowering therapy (ULT); **OR**
 - B. Individual has a contraindication or intolerance to urate-lowering therapy (ULT)

OR

- II. Individual is using for prevention of recurrent pseudogout;

OR

- III. Individual is using for pericarditis with two or more recurrences (DrugPoints BIIa).

Gloperba (colchicine oral solution) may **not** be approved for the following:

- I. Acute treatment of gout flares; **OR**
- II. Treating pain from other causes;

OR

- III. Individual is currently on a medication that is known to inhibit CYP3A4 and/or P-glycoprotein (P-gp); **AND**
- IV. Individual has concomitant renal or hepatic impairment;

OR

*PAGE 1 of 2 08/21/2019
New Program Date 08/21/2019*

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0433-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

V. Individual has both renal and hepatic impairment.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 30, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Khanna D, Fitzgerald JD, Khanna PP, et.al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res.* 2012 Oct;64(10):1431-46.
4. Khanna D, Khanna PP, Fitzgerald JD, et.al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. *Arthritis Care Res.* 2012 Oct;64(10):1447-61.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0433-19